2017 has been seen as a breakthrough year for gene therapy, which could soon be used to cure aggressive forms of cancer, AIDS and even hereditary diseases. Gene therapy is a key technology in the healthcare sector that is regarded as having great potential. Could it be a megatrend that investors will profit from in the near future? Provided the market players involved achieve commercial success, including it in a portfolio at an early stage could add an innovative touch. Besides attractive return prospects, gene therapy offers diversification benefits for a classic investment portfolio that consists mainly of core investments or only contains “conventional” pharmaceuticals.